Microbix Biosystems Inc (MBX.TO)
0.335
0.00 (0.00%)
CAD |
TSX |
Apr 23, 15:57
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 45.74M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -11.69% |
| Valuation | |
| PE Ratio | 12.44 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.087 |
| Price to Book Value | 1.680 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2153 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 76.40% |
Profile
| Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America. |
| URL | https://www.microbix.com |
| Investor Relations URL | https://microbix.com/investors/press-releases/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 15, 2014 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 02, 1999 |
Ratings
Profile
| Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America. |
| URL | https://www.microbix.com |
| Investor Relations URL | https://microbix.com/investors/press-releases/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 15, 2014 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 02, 1999 |